• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. in men with PSA level ≥3.0ng/ml or PCA3 score ≥10. Additional analyses of 4k-panel were 36 done on serum samples. 37 OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcome was defined as 38 sextant biopsy detectable PCa. ROC curve and decision curve analyses were performed to 39 compare the predictive capabilities of %freePSA, PCA3, 4k-panel, the ERSPC RCs, and their 40 combinations in logistic regression models. 41 RESULTS AND LIMITATIONS: PCa was detected in 119 out of 708 men. %freePSA did not 42 perform better univariately or added to the RCs compared to the RCs alone. In 202 men with 43 elevated PSA, the 4k-panel discriminated better than PCA3 when modelled univariately (AUC 44 0.78 vs. 0.62; p=0.01). The multivariable models with PCA3 or 4k-panel were equivalent (AUC 45 of 0.80 for RC 4+DRE). In the total population, PCA3 discriminated better than 4k-panel 46 (univariate AUC 0.63 vs. 0.56, p=0.05). There was no statistically significant difference between 47 the multivariable model with PCA3 (AUC=0.73) vs. the model with 48 p=0.18 ). The multivariable model with PCA3 performed better than the reference model (0.73 49 vs. 0.70, p=0.02). Decision curves confirmed these patterns, although numbers were small. 50 CONCLUSION: Both PCA3 and, to a lesser extent, a 4k-panel have added value to the DRE 51 based ERSPC RC in detecting PCa in pre-screened men. 52 53 PATIENT SUMMARY: In this paper, we studied the added value of novel biomarkers to 54 previously developed risk prediction models for prostate cancer. We found that inclusion of these 55 biomarkers resulted in an increase in predictive ability. 56
INTRODUCTION 58
PSA testing is the mainstay of early detection of prostate cancer (PCa) (1). However, PSA has 59 limited specificity and sensitivity in determining the presence of prostate cancer, which leads to 60 unnecessary biopsies and diagnosis of potentially indolent PCa (2, 3). PSA-based multivariable 61 prediction tools have been developed to improve the prediction of having a biopsy detectable 62 The addition of new biomarkers to an existing prediction tool may increase the accuracy. 67
Novel and promising markers in the field of PCa include the Prostate Cancer Specific Antigen 3 68 (PCA3), a non-coding mRNA, highly over-expressed in PCa tissue (7, 8) which can be assessed 69 using urine obtained after digital rectal exam (DRE). A promising serum-based biomarker is the 70 kallikrein panel (4k-panel), which consists of total-PSA, free-PSA, intact-PSA, and human-71 kallikrein-related peptidase-2 (hK2) (9, 10). The 4k-panel has been shown to increase predictive 72 capability as compared to PSA and DRE alone. 73 In this study, we aimed to assess the added value of %freePSA, PCA3, and 4k-panel to 74 the ERSPC risk calculators (RCs) for pre-screened men. 75
METHODS 77
Participants 78
Participants were recruited from the Dutch part of the ERSPC study (11, 12) . We included 965 79 men who were invited for rescreening (3 rd , 4 th or 5 th time) between October 2007 and February 80 2009. The serum based PSA level and PCA3 were measured in all men. The PCA3 score is the 81 ratio of PCA3:PSA mRNAs multiplied by 1,000 (8). Men with a PSA level ≥3.0ng/ml and/or a 82 PCA3 score ≥10 were invited to undergo a DRE, trans rectal ultrasound (TRUS) and a lateral 83 sextant biopsy. We set the cut-off for PCA3 on ≥10 to evaluate performance characteristics of 84 the PCA3 in comparison to a biopsy indication driven by PSA values of ≥3.0 ng/ml (13). 85
Assessed prostate volume was categorised with cut-points of <30 cc, 30-50 cc, and ≥50 cc (14) . 86
In case of a hypoechogenic lesion, a seventh biopsy was taken. Permission for the present study 87 
Statistical analyses 118
The primary outcome measure was any form of PCa vs. no cancer, detected by a sextant biopsy, 119 in men with elevated PSA levels (≥3.0ng/ml). Secondary, we assessed the predictive value of 120 %freePSA, PCA3, and the 4k-panel in the total population and in the population with 121 PSA<3.0ng/ml. 122
We assessed the predictive value of %freePSA, PCA3, and the 4k-panel, using univariate 123 and multivariable regression models. We refitted the original RCs: RC4 and RC4+DRE to use as 124 the reference. We subsequently refitted the models including %freePSA, PCA3 and/or the 4k-125 panel. We used the area under the ROC curve (AUC) to quantify the predictive accuracy of five 126 models: (i) the first reference model (RC 4+DRE), (ii) the reference model + PCA3, (iii) the 127 reference model + 4k-panel, (iv) the reference model + PCA3 and the 4k-panel, and (v) the 128 reference model + %freePSA. We used the original RC4 (i.e. including information from TRUS) 129
as the second reference model and used the likelihood ratio test for differences between models. 130
We applied decision curve analysis (DCA) (18, 19) to evaluate the potential clinical 131 usefulness of making decisions based on the models including the markers. We estimated net 132 benefit (NB) for prediction models by summing the benefits (true positive biopsies) and 133 subtracting the harms (false positive biopsies). The harms were weighted by a factor related to 134 the relative harm of a missed cancer versus an unnecessary biopsy. This weighting was derived 135 from the threshold probability (pt) of PCa at which a patient would opt for a biopsy. This 136 threshold can vary between men; we used a pt between 0% and 40% (20). The interpretation of a 137 decision curve is straightforward; a model with the highest net benefit at a particular threshold 138 should be chosen over alternative models. The net benefit was used to calculate for the reduction 139 in numbers of biopsies per 100 men with a PSA level of ≥3.0ng/ml (9) and/or a PCA3 score ≥10. 140
We used the following formula: reduction in biopsy per 100 men = (∆NB/(pt/(1-pt)))*100 . These 708 men were invited for rescreening: 339 originated from the 3 rd , 357 originated 151 from the 4 th and 12 originated from the 5 th screening round. Participants were aged 64-75 years at 152 time of the visit. A previous biopsy was taken from 206 (29%) of all men. PCa was found in 119 153 (17%) of the 708 biopsied men, of which 40 in the 202 men with elevated PSA levels (Table 1) . 154
Few men had an abnormal TRUS or DRE. Of 708 men, 503 had a PCA3 score ≥10 and a PSA 155 score <3.0 ng/ml. Total PSA and PCA3 levels differed significantly between men with and 156 without PCa (Table 1) . 157
In men with PSA levels ≥3.0ng/ml the 4k-panel had a higher AUC value as compared to 158 PCA3 when studied univariately (AUC 0.78 vs. 0.62, p=0.01; Table 2 ; Supplementary figures.). 159
The multivariable models with PCA3 or 4k-panel were equivalent (AUC 0.80 for RC 4+DRE, 160 0.78 vs. 0.79 for RC 4 with PCA3 and the 4k-panel respectively). 161
In the total population, PCA3 discriminated better than the 4k-panel (univariate AUC 162 0.63 vs. 0.56, p=0.05, Table 3 ). There was no statistically significant difference between the 163 multivariable model with PCA3 (AUC=0.73) vs. the model with 4k-panel (AUC=0.71, p=0.18). 164
The multivariable model with PCA3 performed better than the reference model (0.73 vs. 0.70, 165 p=0.02). A multivariable model with both markers did not perform better than the multivariable 166 model with PCA3 alone (AUC 0.73 vs. 0.73) in the total dataset. %freePSA did not perform 167 better univariately or added to the RCs compared to the RCs alone in the total population (Table  168 3). 169
Analyses in men with PSA levels <3.0 ng/ml showed no value for the 4k-panel, but some 170 added value of PCA3 (univariate AUC 0.64 (0.58-0.70), AUC 0.70 vs. 0.66 when added to the 171 reference models, p=0.01 for RC4 and p<0.01 for RC4+DRE) (see appendix Table A1 ). 172
In men with elevated PSA levels, the net benefits of all models were higher than in the 173 total dataset (Figure 1 ). In this subgroup the use of a model was clinically useful from a threshold 174 of 5%. The reduction in biopsies per 100 men differed between a threshold of 10 to 30% in the 175 total dataset, in favour of the multivariable model with PCA3 and PCA4 + 4k-panel. In the 176 subgroup of men with elevated PSA, different models were in favour depending on the specific 177 threshold, which also reflected the low number of PCa cases at these thresholds (Figure 2) . 178
The prediction models had added value over biopsy in all men if the threshold for 179 performing a biopsy exceeded 9% (Figure 1-2) . Between thresholds of 9 and 40% the 180 multivariable model with PCA3 orPCA3 + 4k-panel had the highest net benefit and performed 181 better than the reference model at all thresholds. With a cut-point of PSA ≥3.0 ng/m and 182 PCA3>10, reduction in the number of biopsies per 1000 men at a threshold probability of 12.5% 183 was 89 when PCA3 was added, 50 when the 4k-panel was added, and 124 when both the PCA3 184 and the 4k-panel marker were added to the original RC. At a threshold probability of 20%, there 185 was a reduction of 11 biopsies per 1000 men when PCA3 was added to the original RC, and 7 186 per 1000 men when both PCA3 and the 4k-panel were added. In contrast, no reduction in the 187 number of biopsies was noted in men with PSA level ≥3.0 ng/ml. 188
Results were similar for each of the considered reference models (RC4 with DRE or RC4 189 with TRUS, data not shown). 190 DISCUSSION 192 In the current study, adding the 4k-panel to a previously developed PCa risk prediction model 193 increased the predictive value in participants with PSA ≥3.0ng/ml. Adding PCA3 to the 194 previously developed PCa risk prediction model increased the AUC in pre-screened men 195 regardless of total PSA level at time of biopsy. This was equally seen in reference models with 196 and without the inclusion of TRUS and TRUS assessed volume. Therefore, we advise for the 197 model with DRE to estimate prostate volume. 198
In the past, %freePSA has been shown to significantly increase the accuracy of DRE and 199 total PSA (21). Its limited cost and wide availability in labs that run total PSA values are 200 attractive attributes for clinical use. We found very limited predictive value of %freePSA alone 201 or combined with the RCs. 202
The usefulness of PCA3 testing for the detection of PCa and possible reduction of 203 unnecessary biopsies has been shown before (22, 23) . These studies assessed the added value of 204 PCA3 after selecting men for biopsy solely on the basis of a PSA cut-off level. This implies that 205 PCa in men with PSA values below the threshold will be missed. In addition, assessing the added 206 value of PCA3 in men with a previous negative biopsy, initially selected on the basis of an 207 elevated PSA level, is by definition biased. The benefit from PCA3 as compared to PSA is then 208 overoptimistic. To overcome this attribution bias in the current study, men with a PCA3 score 209 ≥10 were biopsied, even if their PSA level was <3.0 ng/ml (13, 24) . 210
Predictions based on the 4k-panel did not differ significantly between cancer and non-211 cancer cases in the total study group, while some markers such as intact-PSA and Hk2 did differ. 212
In the subgroup analyses of men with PSA level ≥3.0, the PCA3 and 4k-panel scores differed 213 significantly between men with and without PCa, whereas intact-PSA and hK2 did not (Table 1) . 214 Free-PSA differed significantly among those in the subgroup men with PSA level ≥3.0. Free 215 PSA may hence be the most relevant element in the 4k-panel for rescreened men with elevated 216 PSA levels. 217
The 4k-panel is developed in men with elevated PSA levels and has up to now only been 218 tested in that particular but clinically most relevant setting. Previous studies showed that 219 predictions based on levels of four kallikrein markers in blood distinguish between 220 pathologically insignificant and aggressive PCa with good accuracy (15, 25) . We confirmed 221 these results with an increase in predictive capability in addition to a risk prediction model that 222 already had an AUC ≥0.7, albeit in a relatively low number of patients. 223
With respect to cost-effectiveness, data suitable for a direct comparison with our study 224 are scarce. While data on the cost effectiveness of PCA3 are weak (26), another comparable but 225 cheaper combination of serum-based sub forms of PSA, the Prostate Health Index (PHI) has 226 been found to be cost-effective for screening purposes (27) . For the current study, we assessed 227 cost-effectiveness with arbitrarily assumed costs for the PCA3 test and for prostate biopsy (€300 228 and €249, (28)). The 4k-panel is not commonly available, and may be cheaper than a PCA3 test 229 (9). When adding PCA3 and/or the 4k-panel to previously developed PCa risk prediction model, 230 less biopsies are needed to find the same amount of cancers (increased net benefit, Fig. 1 and 231 Fig. 2 ). However, this did not result into a substantial reduction in prostate biopsies as compared 232 to the original RCs alone for pts between 0 and 40%, making it very unlikely that the extended 233 risk model will be cost-effective. 234
One limitation of this study was the pre-screened nature of our study cohort. Therefore 235 we compared the performance of models with PCA3 or the 4k-panel to reference models 236 developed for pre-screened men, allowing for a fair comparison. This, and the fact that all men 237 were from the Netherlands, may affect external validity. However, elevated PCA3 scores have 238 particularly been demonstrated to increase the probability of a positive repeat biopsy in men with 239 a prior negative biopsy result, independent of PSA (29, 30) . 240
Another limitation of this study is the small number of men included, specifically men 241 with PSA ≥ 3.0ng/ml. The relative utility of PCA3 and the 4k-panel need to be confirmed. The 242 number of serious cancers was low (N=22, of which 9 in men with PSA levels ≥3.0ng/ml), 243 limiting separate analyses for this group of patients. In men with PSA ≥3.0ng/ml (N=202, of 244 whom 40 had cancer), we used the original RC consisting of 4 variables and extended this with 1 245 or 2 variablesgiving an events per variable (EPV) ratio of 8 or 6.7which could lead to 246 overfitting of the model. Ideally the EPV would be higher, but EPV values from 5 have been 247
shown to be valid in the context of statistical adjustment for baseline risk factors (31). 248
We used sextant biopsying in a repeat screening setting and found a 17% cancer detection 249 rate (N=119), and it is likely that we missed some cases. Even using sextant biopsy for repeat 250 screening, deaths due to PC occurred at a rate of only 0.03%, compared to 0.35% overall ( Figure A1 . ROC curves for the subgroup of 202 men rescreened in the ERSPC trial with PSA ≥3.0ng/ml (Table 2) . 420
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